MarketCapExport financials
Can-Fite BioPharma Ltd. (CANF)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Can-Fite BioPharma Ltd. Income Statement 2025-2011 | CANF
Brief overview of revenue and earnings at Can-Fite BioPharma Ltd.
The figures are compared over a five-year interval. Can-Fite BioPharma Ltd. reported revenue of $763 thousand in 2020 and $405 thousand by 2025. The five-year change reached −46.9%, while CAGR stood at −11.9%. The negative rate indicates weakening core operations.
EBITDA changed from −$14.1 million to −$9.9 million (+29.7%). The operating result outpaced sales and points to improving efficiency. At the operating-margin level, the figure shifted from −1851.5% to −2450.9%. The business retained less EBITDA from each unit of revenue.
The net financial result changed from −$14.4 million to −$9.8 million. The direction improved, yet positive earnings are still absent.
Summary assessment
The indicators point to a weaker financial profile. The positive side is supported by improving net profitability. The overall view is constrained by limited operating profitability, limited revenue growth and weaker operating efficiency. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement Can-Fite BioPharma Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
4.81 M | 1.05 M | 912 K | 2.07 B | 647 M | 706 M | 185 M | 700 M | 1.22 B | 775 M | 757 M | 847 M | 34.6 M | 25.6 M | - |
Shares |
1.65 M | 725 K | 426 K | 816 M | 553 M | 358 M | 85.9 M | 38.9 M | 32.5 M | 28.1 M | 23 M | 17.5 M | 457 K | 335 K | - |
Historical Prices |
2.92 | 1.45 | 2.14 | 2.54 | 1.17 | 1.97 | 2.15 | 18 | 35.7 | 26.9 | 33 | 48.3 | 72.8 | 76.5 | - |
Net Income |
-9.83 M | -7.88 M | -7.63 M | -10.2 M | -12.6 M | -14.4 M | -12.6 M | -6.57 M | 4.99 M | 7.02 M | 5.07 M | 24.5 M | -8.34 M | -5.57 M | -6.7 M |
Revenue |
405 K | 674 K | 743 K | 810 K | 853 K | 763 K | 2.03 M | 3.82 M | 847 K | 170 K | 165 K | - | - | - | 469 K |
Gross Profit |
- | - | - | - | - | - | 2.03 M | 3.82 M | 847 K | 170 K | 165 K | - | - | - | 469 K |
Operating Income |
-9.95 M | -8.13 M | -8.2 M | -10.1 M | -12.8 M | -14.1 M | -12 M | -5.41 M | - | - | - | - | - | - | - |
Interest Expense |
- | - | 561 K | -77 K | 227 K | -304 K | -618 K | -1.15 M | - | - | - | - | - | - | - |
EBITDA |
-9.93 M | -8.12 M | -8.18 M | -10.1 M | -12.8 M | -14.1 M | -12 M | -5.4 M | 5.01 M | 7.04 M | 5.08 M | 24.5 M | -8.81 M | -5.84 M | -4.74 M |
Operating Expenses |
10.4 M | 8.8 M | 8.94 M | 10.9 M | - | - | 14 M | 9.23 M | 8.22 M | 8.8 M | 6.58 M | 7.13 M | - | - | 5.27 M |
General and Administrative Expenses |
3.66 M | 3.05 M | 2.96 M | 126 K | 3.84 M | 158 K | 132 K | 130 K | 2.96 M | 2.73 M | 2.72 M | 11.6 M | 4.52 M | - | - |
All numbers in USD currency
Quarterly Income Statement Can-Fite BioPharma Ltd.
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
1.65 M | 3.41 B | 725 K | 1.82 B | 426 K | 1.2 B | - | - | - | - | 816 M | - | 516 M | - | 464 M | - | 411 M | - | 121 M | - | - | - | 40.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-9.83 M | -4.88 M | -7.88 M | -3.96 M | -7.63 M | -4.22 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
405 K | 202 K | 674 K | 316 K | 743 K | 392 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-9.95 M | -4.9 M | -8.13 M | -4.09 M | -8.2 M | -4.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | - | - | - | 561 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-9.93 M | -4.88 M | -8.12 M | -4.09 M | -8.18 M | -4.49 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
10.4 M | - | 8.8 M | - | 8.94 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
3.66 M | 2.07 M | 3.05 M | 1.52 M | 2.96 M | 1.47 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Can-Fite BioPharma Ltd. (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Britain
Israel
Germany
Canada
Russia
Schweiz
